Transmucosal Delivery of Peptides and Proteins Through Nanofibers: Current Status and Emerging Developments

• Published in: AAPS PharmSciTech 2024-04, Vol.25 (4), p.74-74, Article 74
• Main Authors: Gavali, Priyanka, Desai, Jagruti, Shah, Pranav, Sawarkar, Sujata
• Format: Article
• Language: English
• Subjects: Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Drug Delivery Systems - methods; Female; Humans; Nanofibers - chemistry; Peptides; Pharmaceutical Preparations; Pharmacology/Toxicology; Pharmacy; Proteins; Review Article
• ISSN: 1530-9932; 1530-9932
• DOI: 10.1208/s12249-024-02794-x

Advancements in recombinant DNA technology have made proteins and peptides available for diagnostic and therapeutic applications, but their effectiveness when taken orally leads to poor patient compliance, requiring clinical administration. Among the alternative routes, transmucosal delivery has the advantage of being noninvasive and bypassing hepato-gastrointestinal clearance. Various mucosal routes—buccal, nasal, pulmonary, rectal, and vaginal—have been explored for delivering these macromolecules. Nanofibers, due to their unique properties like high surface-area-to-volume ratio, mechanical strength, and improved encapsulation efficiency, serve as promising carriers for proteins and peptides. These nanofibers can be tailored for quick dissolution, controlled release, enhanced encapsulation, targeted delivery, and improved bioavailability, offering superior pharmaceutical and pharmacokinetic performance compared to conventional methods. This leads to reduced dosages, fewer side effects, and enhanced patient compliance. Hence, nanofibers hold tremendous potential for protein/peptide delivery, especially through mucosal routes. This review focuses on the therapeutic application of proteins and peptides, challenges faced in their conventional delivery, techniques for fabricating different types of nanofibers and, various nanofiber-based dosage forms, and factors influencing nanofiber generation. Insights pertaining to the precise selection of materials used for fabricating nanofibers and regulatory aspects have been covered. Case studies wherein the use of specific protein/peptide-loaded nanofibers and delivered via oral/vaginal/nasal mucosa for diagnostic/therapeutic use and related preclinical and clinical studies conducted have been included in this review. Graphical Abstract